Faecal microbiota transplantation for severe, refractory Clostridioides difficile infection: a multicentre real‐world experience

BACKGROUND: Severe Clostridioides difficile infection (CDI) is associated with substantial morbidity and mortality. Although most patients respond to CDI-directed antimicrobial therapy, a subset develops refractory disease. Faecal microbiota transplantation (FMT) is established for recurrent CDI, but data supporting its use in severe, refractory CDI remain limited. AIMS: To evaluate the safety and effectiveness of FMT in hospitalised patients with severe, refractory CDI across tertiary centres. METHODS: This was a retrospective multicentre study of adults with severe, refractory CDI who underwent FMT at three tertiary hospitals in Western Australia between January 2021 and April 2025. Severe CDI was defined according to Australasian Society of Infectious Diseases criteria and refractory disease as failure to demonstrate clinical improvement following appropriate CDI-directed antimicrobial therapy. Primary cure was defined as resolution without recurrence within 90 days following a single FMT. Secondary outcomes included secondary cure, colectomy, FMT-related complications and hospital length of stay. RESULTS: Fourteen patients underwent FMT for severe, refractory CDI. Median age was 68.5 years (range 32-84), 57.1% were female, and 71.4% were immunosuppressed. Median Charlson Comorbidity Index was 5.5 (range 0-11). FMT was delivered via colonoscopy, flexible sigmoidoscopy or nasogastric tube. Median sessions was 1.5 (range 1-4); five (35.7%) patients received consolidative antibiotics following repeat FMT. Primary cure after a single FMT was achieved in seven (50%) patients. The remaining seven required repeat FMT, with a secondary cure rate of 100% at 3 months. One patient died from an unrelated cause. No patients required colectomy, experienced recurrence or FMT-related complications. Median hospital stay was 24.5 days (range 7-65). CONCLUSION: FMT was associated with high rates of clinical cure as salvage therapy for hospitalised patients with severe, refractory CDI. While only half achieved primary cure after a single FMT, sequential FMT achieved a secondary cure rate of 100%. Further studies are needed to define optimal treatment protocols.

Authors

Institutions

Publication Details

Journal
Internal Medicine Journal
Published
2026-11-13
DOI
https://doi.org/10.1111/imj.70702
Primary Topic
Clostridium difficile and Clostridium perfringens research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Faecal microbiota transplantation for severe, refractory Clostridioides difficile infection: a multicentre real‐world experience

Angel Li, Oliver Waters, Shankar Menon, Thomas Gliddon et al.
Internal Medicine Journal
Clostridium difficile and Clostridium perfringens research
article

Faecal microbiota transplantation for severe, refractory Clostridioides difficile infection: a multicentre real‐world experience

Angel Li, Oliver Waters, Shankar Menon, Thomas Gliddon, Jesica C. Makanyanga, Andrew Chin, Claudia Gardner
article en

Abstract

BACKGROUND: Severe Clostridioides difficile infection (CDI) is associated with substantial morbidity and mortality. Although most patients respond to CDI-directed antimicrobial therapy, a subset develops refractory disease. Faecal microbiota transplantation (FMT) is established for recurrent CDI, but data supporting its use in severe, refractory CDI remain limited. AIMS: To evaluate the safety and effectiveness of FMT in hospitalised patients with severe, refractory CDI across tertiary centres. METHODS: This was a retrospective multicentre study of adults with severe, refractory CDI who underwent FMT at three tertiary hospitals in Western Australia between January 2021 and April 2025. Severe CDI was defined according to Australasian Society of Infectious Diseases criteria and refractory disease as failure to demonstrate clinical improvement following appropriate CDI-directed antimicrobial therapy. Primary cure was defined as resolution without recurrence within 90 days following a single FMT. Secondary outcomes included secondary cure, colectomy, FMT-related complications and hospital length of stay. RESULTS: Fourteen patients underwent FMT for severe, refractory CDI. Median age was 68.5 years (range 32-84), 57.1% were female, and 71.4% were immunosuppressed. Median Charlson Comorbidity Index was 5.5 (range 0-11). FMT was delivered via colonoscopy, flexible sigmoidoscopy or nasogastric tube. Median sessions was 1.5 (range 1-4); five (35.7%) patients received consolidative antibiotics following repeat FMT. Primary cure after a single FMT was achieved in seven (50%) patients. The remaining seven required repeat FMT, with a secondary cure rate of 100% at 3 months. One patient died from an unrelated cause. No patients required colectomy, experienced recurrence or FMT-related complications. Median hospital stay was 24.5 days (range 7-65). CONCLUSION: FMT was associated with high rates of clinical cure as salvage therapy for hospitalised patients with severe, refractory CDI. While only half achieved primary cure after a single FMT, sequential FMT achieved a secondary cure rate of 100%. Further studies are needed to define optimal treatment protocols.

Internal Medicine Journal
Royal Perth Hospital (AU), Fiona Stanley Hospital (AU), Sir Charles Gairdner Hospital (AU)
Good health and well-being
Clostridium difficile and Clostridium perfringens research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon